Investor Relations
Investor Relations Contact:
LHA
Anne Marie Fields
212-838-3777
afields@lhai.com
or
Bruce Voss
310-691-7100
bvoss@lhai.com

Media Contact
Rooney & Associates
Terry Rooney
212-223-0689
trooney@rooneyco.com
or
Marion Janic
212-223-4017
mjanic@rooneyco.com

Press Releases

All Releases
View Summary OPKO Health to Participate at Three Investment Conferences in December
Nov 30, 2016
PDF 16.3 KB
View Summary OPKO Announces U.S. Launch of RAYALDEE™
Nov 23, 2016
PDF 67.8 KB
View Summary OPKO Presents Data on RAYALDEE® at ASN Kidney Week 2016
Nov 17, 2016
PDF 64.6 KB
View Summary OPKO Health Reports Third Quarter Financial and Operating Results
Nov 7, 2016
PDF 35.9 KB
View Summary OPKO to Announce Third Quarter Operating and Financial Results on November 7, 2016
Nov 3, 2016
PDF 15.0 KB
View Summary OPKO Health Enters Companion Animal Health Market
Oct 27, 2016
PDF 15.9 KB
View Summary OPKO Health Appoints Dr. Benjamin Solomon as Managing Director of GeneDx
Sep 27, 2016
PDF 14.6 KB
View Summary OPKO Health to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Sep 19, 2016
PDF 11.1 KB
View Summary OPKO Health Appoints Jane Pine Wood as Chief Legal and Compliance Officer of BioReference Laboratories
Sep 13, 2016
PDF 15.2 KB
View Summary OPKO to Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data at the 55th Annual Meeting of the European Society for Paediatric Endocrinology
Sep 6, 2016
PDF 21.7 KB
View Summary OPKO Health to Participate in Upcoming September Conferences
Sep 1, 2016
PDF 14.3 KB
View Summary OPKO Health Completes Acquisition of Transition Therapeutics
Aug 31, 2016
PDF 14.7 KB
View Summary Transition Therapeutics Shareholders Approve Acquisition by OPKO Health
Aug 26, 2016
PDF 14.5 KB
View Summary OPKO Health Responds to Law Firm Notice of Investigation
Aug 23, 2016
PDF 13.1 KB
View Summary OPKO Health Reports Improved Financial and Operating Results
Aug 8, 2016
PDF 29.9 KB
View Summary OPKO to Announce Second Quarter Operating and Financial Results on August 8, 2016
Aug 3, 2016
PDF 13.5 KB
View Summary OPKO Health to Acquire Transition Therapeutics
Jun 30, 2016
PDF 24.1 KB
View Summary FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease
Jun 21, 2016
PDF 72.3 KB
View Summary OPKO Health to Host Analyst & Investor Day in New York City on June 15
Jun 14, 2016
PDF 12.1 KB
View Summary OPKO Health Announces Move to NASDAQ Stock Market
Jun 13, 2016
PDF 14.2 KB
Showing 1-20 of 304 Page: 1 2 3 4 5 ... 16  Next 20

Email  Sign up for email alerts